Key House Republicans on Tuesday introduced long-awaited—and contentious—legislation to
overhaul the 340B program.
340B Lobbying Activity Experiences Historic Surge
The hiring of lobbyists in the congressional legislative fight over 340B was dominated by pharmaceutical firms and provider-manufacturer alliances in [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.